Some results suggested that the administration of PPAR ligands such as 15d-PGJ2 may be a novel therapeutic strategy for MS because PPAR ligands efficiently reduced the severity of the inflammation by reducing both the secretion of encephalitogenic T-cells and cytokines and the consequent demyelination [127]. This evidence concerns the gene PPARA and myeloid sarcoma.